System, a telehealth platform that connects patients seeking peptide treatments with licensed clinicians and United States compounding pharmacies, reportedly raised $12.6 million. Axios said CEO Adam Steinle provided the figure and described the financing as bringing System’s total capital raised to $20.3 million.
A patient enters through System’s online clinic, shares a health history and receives an evaluation from a licensed clinician. If the clinician prescribes a treatment, a compounding pharmacy prepares it for shipment to the patient. System lists glutathione, MIC+B12, NAD+ and sermorelin among its offerings and says availability across all 50 states remains subject to state telehealth rules.
That workflow makes System a virtual clinic rather than a storefront selling peptides without a prescription. The company says its products undergo third-party laboratory testing, its clinicians are background-checked and reviewed against the National Practitioner Data Bank, and treatments come from FDA-registered compounding pharmacies. Steinle separately said the clinic has served tens of thousands of patients since its March launch; that is a company-reported figure.
System is now trying to control more of the fulfillment behind those prescriptions. It says it has a compounding pharmacy in its network and is building a 14,000-square-foot facility in Columbia, Missouri. Steinle said the site is intended as a blueprint for a national pharmacy network that System’s own clinic and outside medical groups could use, while those groups retain their patient relationships.
The financing’s public description is inconsistent. Axios reported $12.6 million for the latest raise and $20.3 million in cumulative funding, while System’s release called $20 million “new funding.” Steinle’s own announcement said the company had raised more than $20 million overall, without calling that the latest round’s size. System named Patron Fund, Will Ventures, Vine, Courtside, Daybreak, SV Angel and RiverPark Ventures as investors but did not identify a lead in its release.
The capital therefore backs an operational shift from coordinating prescriptions and outside fulfillment toward controlling more of the pharmacy infrastructure itself. The consequential test is whether System can add manufacturing capacity and serve outside medical groups while keeping its clinician oversight, sourcing and testing controls consistent as patient volume grows.